- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06015867
Effect of Sourdough Bread Consumption on Postprandial Responses, Appetite Regulation and Energy Intake (SPAR)
Effect of Sourdough Bread Consumption on Postprandial Responses, Appetite Regulation and Energy Intake at the Subsequent Meal (SPAR Study)
Study Overview
Status
Detailed Description
The primary aim of this study will be to evaluate the impact of an alternative starter culture that produces high levels of lactic acid on appetite regulation (subjective satiety and energy intake at the subsequent meal). The second aim will be to identify mechanistic parameters that may explain the observed effects, including glycaemic and insulin response, and gastric emptying rate. In addition, habitual physical activity levels, and mood and stress levels of the subjects will be evaluated as potential covariates of appetite regulation.
It is hypothesized that:
Sourdough breads fermented with the alternative starter culture that produce high concentrations of lactic acid will reduce glucose response via lower starch digestibility and/or slower gastric emptying rate. The reduced glycaemic response will lead to higher satiety and lower energy intake at the subsequent meal (more than 10%).
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Leuven, Belgium, 3000
- UZ Leuven
-
-
Vlaams Brabant
-
Leuven, Vlaams Brabant, Belgium, 3000
- KU Leuven/UZ Leuven
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Female and male participants
- age range 18 - 50
- BMI range 18.5 - 25.0 kg/m2 at screening visit
- Regular eating pattern (3 meals per day on at least 5 days per week)
- Stable body weight for the last 6 months
Exclusion Criteria:
- Currently smoking (has smoked in the last 28 days) or willingness to smoke during the study period
- Pregnancy, lactation or wish to become pregnant during the study period
- Family history of diabetes
- Previous or current gastrointestinal or endocrine disorders
- Previous or current substance/alcohol dependence or abuse (> 2 units per day/14 units per week)
- Coeliac disease or gluten sensitivity
- Use of pre- or probiotics within one month preceding the study
- Use of antibiotics within 3 months preceding the study
- Excessive concern about eating habits or body weight as evidenced from scores < 18 on the restraint and disinhibition subscales of the Three-Factor Eating Questionnaire (Stunkard & Messick, 1985)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Control Bread: Wholemeal Yeast Bread
Wholemeal bread, containing mainly of wholemeal flour, water and bakers' yeast will be used as the control test bread.
|
Single administration of 150g wholemeal long-time processed bread with baker's yeast, with no lactic acid (control).
Single administration of 150g wholemeal long-time processed sourdough bread (with alternative lactic acid bacteria and yeast) high in lactic acid concentration.
|
|
Active Comparator: Wholemeal Sourdough Bread
Wholemeal sourdough bread, containing mainly of wholemeal flour, water and added sourdough co-culture (consisting of W.anom.+ C.crust strain).
|
Single administration of 150g wholemeal long-time processed bread with baker's yeast, with no lactic acid (control).
Single administration of 150g wholemeal long-time processed sourdough bread (with alternative lactic acid bacteria and yeast) high in lactic acid concentration.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Food intake at subsequent meal
Time Frame: During test day 1 (240 minutes after ingestion of breakfast)
|
Weighted amounts of ad-libitum food offered minus the weighted leftovers
|
During test day 1 (240 minutes after ingestion of breakfast)
|
|
Food intake at subsequent meal
Time Frame: During test day 2 (240 minutes after ingestion of breakfast)
|
Weighted amounts of ad-libitum food offered minus the weighted leftovers
|
During test day 2 (240 minutes after ingestion of breakfast)
|
|
Appetite measurements
Time Frame: During test day 1 (up to 4 hours)
|
Appetite in response to test meal, will be measured using 100 millimeter (mm) Visual Analogue Scales (VAS), with 0 being the minimum value (not at all) and 100 being the maximum value (extremely). Measurements will be taken: before eating (i.e. 0 minute) and at respective time points after completion of test meal (I.e. 15, 30, 45, 60, 75, 90, 105, 120, 135, 150, 165, 180, 195, 210, 225, 240 minutes). |
During test day 1 (up to 4 hours)
|
|
Appetite measurements
Time Frame: During test day 2 (up to 4 hours)
|
Appetite in response to test meal, will be measured using 100 millimeter (mm) Visual Analogue Scales (VAS), with 0 being the minimum value (not at all) and 100 being the maximum value (extremely). Measurements will be taken: before eating (i.e. 0 minute) and at respective time points after completion of test meal (I.e. 15, 30, 45, 60, 75, 90, 105, 120, 135, 150, 165, 180, 195, 210, 225, 240 minutes). |
During test day 2 (up to 4 hours)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Gastric emptying rate
Time Frame: During test day 1 (up to 4 hours)
|
Gastric emptying rate will be measured through 13C-octanoic acid breath samples collected before eating (i.e.
0 minute) and at respective time points after completion of test meal (I.e. 15, 30, 45, 60, 75, 90, 105, 120, 135, 150, 165, 180, 195, 210, 225, 240 minutes).
|
During test day 1 (up to 4 hours)
|
|
Gastric emptying rate
Time Frame: During test day 2 (up to 4 hours)
|
Gastric emptying rate will be measured through 13C-octanoic acid breath samples collected before eating (i.e.
0 minute) and at respective time points after completion of test meal (I.e. 15, 30, 45, 60, 75, 90, 105, 120, 135, 150, 165, 180, 195, 210, 225, 240 minutes).
|
During test day 2 (up to 4 hours)
|
|
Glucose response
Time Frame: During test day 1 (up to 4 hours)
|
Blood glucose response will be measured through blood samples collected via placed catheter before eating and at respective time points after completion of test meal (I.e.
0, 15, 30, 45, 60, 75, 90, 105, 120, 150, 180, 210, 240 minutes)
|
During test day 1 (up to 4 hours)
|
|
Glucose response
Time Frame: During test day 2 (up to 4 hours)
|
Blood glucose response will be measured through blood samples collected via placed catheter before eating and at respective time points after completion of test meal (I.e.
0, 15, 30, 45, 60, 75, 90, 105, 120, 150, 180, 210, 240 minutes)
|
During test day 2 (up to 4 hours)
|
|
Insulin response
Time Frame: During test day 1 (up to 4 hours)
|
Blood C-peptide (as indicator of insulin response) will be measured through blood samples collected via placed catheter before eating and at respective time points after completion of test meal (I.e.
0, 15, 30, 45, 60, 75, 90, 105, 120, 150, 180, 210, 240 minutes)
|
During test day 1 (up to 4 hours)
|
|
Insulin response
Time Frame: During test day 2 (up to 4 hours)
|
Blood C-peptide (as indicator of insulin response) will be measured through blood samples collected via placed catheter before eating and at respective time points after completion of test meal (I.e.
0, 15, 30, 45, 60, 75, 90, 105, 120, 150, 180, 210, 240 minutes)
|
During test day 2 (up to 4 hours)
|
|
Subjective stress ratings
Time Frame: During test day 1 (up to 4 hours)
|
Subjective stress, will be measured using 100 millimeter (mm) Visual Analogue Scales (VAS), with with 0 being the minimum value (not at all) and 100 being the maximum value (extremely). Measurements will be takem: before eating (i.e. -15 minute) and at respective time points after completion of test meal (I.e. 0, 60, 120, 180, 240 minutes). |
During test day 1 (up to 4 hours)
|
|
Subjective stress ratings
Time Frame: During test day 2 (up to 4 hours)
|
Subjective stress, will be measured using 100 millimeter (mm) Visual Analogue Scales (VAS), with with 0 being the minimum value (not at all) and 100 being the maximum value (extremely). Measurements will be takem: before eating (i.e. -15 minute) and at respective time points after completion of test meal (I.e. 0, 60, 120, 180, 240 minutes). |
During test day 2 (up to 4 hours)
|
|
Physical activity questionnaire
Time Frame: At the end of test day 1
|
Questionnaire about habitual physical activity over the past 1 week.
Subjects will have to report how many days per week and for how many minus they perform vigorous, moderate or relaxed physical activity.
|
At the end of test day 1
|
|
Physical activity questionnaire
Time Frame: At the end of test day 2
|
Questionnaire about habitual physical activity over the past 1 week.
Subjects will have to report how many days per week and for how many minus they perform vigorous, moderate or relaxed physical activity.
|
At the end of test day 2
|
|
Mood related questionnaires - The Positive and Negative Affect Schedule (PANAS scale)
Time Frame: At the end of test day 1
|
Mood related questionnaires over the past 1 week.
Subjects will have to evaluate the extent they have felt certain feelings over the past week.
Score will vary between 1 (Very slightly or not at all) to 5 (Extremely).
|
At the end of test day 1
|
|
Mood related questionnaires - The Positive and Negative Affect Schedule (PANAS scale)
Time Frame: At the end of test day 2
|
Mood related questionnaires over the past 1 week.
Subjects will have to evaluate the extent they have felt certain feelings over the past week.
Score will vary between 1 (Very slightly or not at all) to 5 (Extremely).
|
At the end of test day 2
|
|
Mood related questionnaires - Perceived Stress Scale - 10 items (PSS-10)
Time Frame: At the end of test day 1
|
Mood related questionnaires over the past 1 week.
Subjects will have to evaluate how ofter have felt certain feelings over the past week.
Score will vary between 0 (Never) to 4 (Very often).
|
At the end of test day 1
|
|
Mood related questionnaires - Perceived Stress Scale - 10 items (PSS-10)
Time Frame: At the end of test day 2
|
Mood related questionnaires over the past 1 week.
Subjects will have to evaluate how ofter have felt certain feelings over the past week.
Score will vary between 0 (Never) to 4 (Very often).
|
At the end of test day 2
|
|
Mood related questionnaires - Depression, Anxiety, Stress Scales - 21 items (DASS-21)
Time Frame: At the end of test day 1
|
Mood related questionnaires over the past 1 week.
Subjects will have to evaluate es how much the statement applied to them over the last week.
Score will vary between 0 (Did not apply to me at all) to 3 (Applied to me very much or most of the time).
|
At the end of test day 1
|
|
Mood related questionnaires - Depression, Anxiety, Stress Scales - 21 items (DASS-21)
Time Frame: At the end of test day 2
|
Mood related questionnaires over the past 1 week.
Subjects will have to evaluate es how much the statement applied to them over the last week.
Score will vary between 0 (Did not apply to me at all) to 3 (Applied to me very much or most of the time).
|
At the end of test day 2
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Kristin Verbeke, PhD, KU Leuven
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- S64824 - B3222020000339
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gastric Emptying
-
Mayo ClinicCompletedGastric EmptyingUnited States
-
Air Force Military Medical University, ChinaCompleted
-
Coombe Women and Infants University HospitalCompleted
-
Kangbuk Samsung HospitalUnknown
-
Maastricht University Medical CenterUnilever R&DCompleted
-
Guy's and St Thomas' NHS Foundation TrustCompleted
-
University Children's Hospital, ZurichCompleted
-
Federal University of Minas GeraisNestle Health ScienceRecruiting
-
Columbia UniversityRecruiting
-
Medical University of ViennaCompleted
Clinical Trials on Dietary Intervention with Wholemeal Bread with Yeast
-
KU LeuvenCompletedAppetite Regulation | Energy IntakeBelgium
-
KU LeuvenRecruitingBody Weight Changes | Overweight and Obesity | Eating Behavior | Appetite Regulation | Energy IntakeBelgium
-
Bispebjerg HospitalCompleted
-
University of AberdeenUnknownNon Coeliac Gluten SensitivityUnited Kingdom
-
University of AberdeenCompletedCardiovascular DiseaseUnited Kingdom
-
Azienda Ospedaliero-Universitaria Consorziale Policlinico...Ospedali Riuniti di FoggiaCompleted
-
Universidade do PortoCenter for Health Technology and Services Research; Project VALORINTEGRADOR...CompletedHealthy VolunteersPortugal
-
Harokopio UniversityJOTIS S.A. FOOD INDUSTRY, GREECECompleted
-
Ege UniversityCompletedObesity | Celiac Disease | Blood Glucose | Flour SensitivityTurkey
-
Swiss Federal Institute of TechnologyCheikh Anta Diop University, SenegalCompletedAnemia; Deficiency, Nutritional, With Poor Iron AbsorptionSenegal